Literature DB >> 3348737

Splenectomy and the induction of murine colon cancer.

C C Hull1, P Galloway, N Gordon, S L Gerson, N Hawkins, T A Stellato.   

Abstract

The influence of a functional spleen on induction and growth of cancer is unknown. Both beneficial and detrimental results have been observed in tumor-bearing hosts following splenectomy. We examined the effect of splenectomy, splenic autotransplantation, and splenic preservation on the induction and growth of 1,2-dimethylhydrazine (DMH)-induced murine colon cancer. Following splenectomy there was a significant increase in malignant tumors but no increase in benign tumors. To rule out the possibility that splenectomy increased the carcinogenicity of DMH by decreasing the capacity for DNA repair in colon cells, the units of 06-alkylguanine DNA alkyltransferase were measured in tumor-free and malignant colon tissue from both splenectomized and control rats. This repair protein was chosen because it is known to protect cells from the mutagenic effects of methylating agents. There was no significant difference in the alkyltransferase activity of tumor-free colon vs malignant tumor or between treatment regimens. Thus, the ability of the spleen to protect rats from the induction of malignant colon tumors induced by DMH is most likely due to preservation of immunologic surveillance in the host.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348737     DOI: 10.1001/archsurg.1988.01400280072012

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  11 in total

1.  Two-color flow cytometric analysis of splenic lymphocyte subpopulations in patients with gastric cancer.

Authors:  M Takahashi; S Fujimoto; M Takai; K Ohno; F Endoh; Y Masuda; Y Masuda; G Obata
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

Review 2.  [Role of the spleen in tumor surgery].

Authors:  U Wolters; H W Keller; H Pichlmaier
Journal:  Langenbecks Arch Chir       Date:  1991

3.  The paradoxical effects of splenectomy on tumor growth.

Authors:  Richmond T Prehn
Journal:  Theor Biol Med Model       Date:  2006-06-26       Impact factor: 2.432

4.  Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up.

Authors:  Sigurdur Y Kristinsson; Gloria Gridley; Robert N Hoover; David Check; Ola Landgren
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

5.  Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response.

Authors:  Liran Levy; Inbal Mishalian; Rachel Bayuch; Lida Zolotarov; Janna Michaeli; Zvi G Fridlender
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

6.  Spleen-dependent turnover of CD11b peripheral blood B lymphocytes in bovine leukemia virus-infected sheep.

Authors:  Arnaud Florins; Nicolas Gillet; Becca Asquith; Christophe Debacq; Geneviève Jean; Isabelle Schwartz-Cornil; Michel Bonneau; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

7.  Evaluation of the risk factors for venous thromboembolism post splenectomy - A ten year retrospective cohort study in St James's hospital.

Authors:  Manal Abduljalil; Jean Saunders; Dearbhla Doherty; Marthinus Dicks; Catherine Maher; Brian Mehigan; Richard Flavin; Catherine M Flynn
Journal:  Ann Med Surg (Lond)       Date:  2021-05-08

8.  Earlier onset of delta-retrovirus-induced leukemia after splenectomy.

Authors:  Arnaud Florins; Michal Reichert; Becca Asquith; Amel-Baya Bouzar; Geneviève Jean; Carole François; Agnieszka Jasik; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

9.  Adverse prognostic impact of splenectomy on survival in gastric carcinoma patients: Regression and propensity score matching analysis of 1074 patients.

Authors:  Oh Jeong; Ho Goon Kim; Seong Yeob Ryu; Young Kyu Park; Mi Ran Jung
Journal:  PLoS One       Date:  2018-09-11       Impact factor: 3.240

10.  Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition.

Authors:  M Kuttke; E Sahin; J Pisoni; S Percig; A Vogel; D Kraemmer; L Hanzl; J S Brunner; H Paar; K Soukup; A Halfmann; A M Dohnal; C W Steiner; S Blüml; J Basilio; B Hochreiter; M Salzmann; B Hoesel; G Lametschwandtner; R Eferl; J A Schmid; G Schabbauer
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.